Loading company…
ID 212153667 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პრეპარატების წარმოება.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15 | 53 | 112 | 114 | 216 | 265 | 251 | +59.8% |
| Total Non-Current Assets | 11,119 | 9,868 | 13,185 | 14,895 | 16,207 | 18,219 | 18,847 | +9.2% |
| TOTAL ASSETS | 11,134 | 9,920 | 13,298 | 15,008 | 16,423 | 18,484 | 19,098 | +9.4% |
| Total Current Liabilities | 2,509 | 2,242 | 3,021 | 1,408 | 599 | 1,384 | 888 | -15.9% |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| TOTAL LIABILITIES | 2,509 | 2,242 | 3,021 | 1,408 | 599 | 1,384 | 888 | -15.9% |
| Total Equity | 8,625 | 7,678 | 10,277 | 13,600 | 15,825 | 17,100 | 18,209 | +13.3% |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | ||||||||
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Equivalents | 932 | 179 | 471 | 1,637 | 1,292 | 1,093 | 1,264 | +5.2% |
| Net Debt | -932 | -179 | -471 | -1,637 | -1,292 | -1,093 | -1,264 | +5.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).